Table 4.

Seroconversion rates and geometric mean titers after vaccination compared to before vaccination (per-protocol population, homologous response)

	Time point	Value	KD-287 (n = 93)	JEV-GCC (n = 95)	*Difference/Ratio
SCR	Seropositive at baseline	n (%)	0 (0.0)	1 (1.0)
	Seropositive at baseline	95% CI
	After 2^nd dose	n (%)	93 (100.0)	93 (97.9)	2.1
	After 2^nd dose	95% CI			(−0.78, 4.99)
	Before 3^rd dose	n (%)	93 (100.0)	90 (94.7)	5.3
	Before 3^rd dose	95% CI			(0.77, 9.75)
	After 3^rd dose	n (%)	93 (100.0)	94 (98.9)	1.1
	After 3^rd dose	95% CI	(100.0, 100.0)	(96.9, 100.0)	(−1.00, 3.10)
GMT	Before Vaccination	log10ⁿ	5	5	1.0
	Before Vaccination	95% CI	(5, 6)		(1.0, 1.1)
	After 2^nd dose	log10ⁿ	601	107	5.6^†
	After 2^nd dose	95% CI	(509, 709)	(84, 137)	(4.2, 7.5)
	Before 3^rd dose	log10ⁿ	917	45	20.1^†
	Before 3^rd dose	95% CI	(757, 1110)	(36, 56)	(15.2, 26.7)
	After 3^rd dose	log10ⁿ	13347	967	13.8^†
	After 3^rd dose	95% CI	(11455, 15551)	(798, 1172)	(10.8, 17.6)

SCR, seroconversion rate; GMT, geometric mean titer; CI, confidence interval.

*Difference is KD-287 minus JEV-GCC for SCR and ratio is KD-287 divided by JEV-GCC for GMT.

^†The p-value was calculated using the t-test for GMT; p < 0.001 in all.